Literature DB >> 25629654

Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States.

Volker Foos1, Nebibe Varol, Bradley H Curtis, Kristina S Boye, David Grant, James L Palmer, Phil McEwan.   

Abstract

OBJECTIVE: To identify the direct and indirect costs of hypoglycemia in patients with Type 1 or Type 2 diabetes mellitus (DM) in the US setting.
METHODS: A literature review was conducted to identify and review studies that reported data on the economic burden of hypoglycemia and the related medical resource consumption or productivity loss related to hypoglycemia in patients with Type 1 or Type 2 DM. Relevant information was collated in an economic model to assess the direct and indirect costs following severe and non-severe hypoglycemic events in Type 1 and Type 2 DM.
RESULTS: Detailed evidence of the medical cost burden of hypoglycemic events was identified from 14 studies. For both Type 1 and Type 2 DM, episodes requiring assistance from a healthcare practitioner were identified as particularly costly and amounted to $1161 per episode (direct costs) compared with episode costs of $66 and $11 for events requiring third-party (non-medical) assistance and events managed by self-treatment, respectively. Indirect costs associated with severe hypoglycemia requiring non-medical assistance, severe hypoglycemia requiring medical assistance, and non-severe hypoglycemia were predicted to be $242, $160, and $11 for patients with Type 1 diabetes and $579, $176, and $11 for patients with Type 2 diabetes, respectively.
CONCLUSION: Both severe and non-severe hypoglycemia incur substantial healthcare costs. Failure to account for these costs may under-estimate the value of management strategies that minimize hypoglycemia risk.

Entities:  

Keywords:  Episode costs; Health-economic-evaluation; Hypoglycemia; Medical resources; Type 1 diabetes; Type 2 diabetes

Mesh:

Year:  2015        PMID: 25629654     DOI: 10.3111/13696998.2015.1006730

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  33 in total

1.  Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial.

Authors:  Wen Wan; M Reza Skandari; Alexa Minc; Aviva G Nathan; Parmida Zarei; Aaron N Winn; Michael O'Grady; Elbert S Huang
Journal:  Med Decis Making       Date:  2018-11       Impact factor: 2.583

2.  Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial.

Authors:  Wen Wan; M Reza Skandari; Alexa Minc; Aviva G Nathan; Aaron Winn; Parmida Zarei; Michael O'Grady; Elbert S Huang
Journal:  Diabetes Care       Date:  2018-04-12       Impact factor: 19.112

3.  The Need to Change Regulatory Evaluation of Hypoglycemia in Trials of Diabetes Treatments.

Authors:  David C Klonoff; Alexander Fleming; Robert Gabbay
Journal:  J Diabetes Sci Technol       Date:  2019-11-19

4.  Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.

Authors:  Kelvin Lingjet Tran; Young In Park; Shalin Pandya; Navin John Muliyil; Brandon David Jensen; Kovin Huynh; Quang T Nguyen
Journal:  Am Health Drug Benefits       Date:  2017-06

5.  Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.

Authors:  Thomas R Pieber; Ronnie Aronson; Ulrike Hövelmann; Julie Willard; Leona Plum-Mörschel; Kim M Knudsen; Benedikte Bandak; Ramin Tehranchi
Journal:  Diabetes Care       Date:  2021-06-01       Impact factor: 19.112

6.  Impact of pharmacist outreach on glucagon prescribing.

Authors:  Nakiya Whitfield; Patrick Gregory; Beiyu Liu; Susan Spratt; Benjamin H Smith
Journal:  J Am Pharm Assoc (2003)       Date:  2022-01-31

7.  Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among U.S. adults with diabetes.

Authors:  Rozalina G McCoy; Jeph Herrin; Kasia J Lipska; Nilay D Shah
Journal:  J Diabetes Complications       Date:  2018-04-24       Impact factor: 2.852

8.  Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.

Authors:  Johannes Pöhlmann; Beth D Mitchell; Sanjay Bajpai; Beatrice Osumili; William J Valentine
Journal:  J Diabetes Sci Technol       Date:  2019-01-30

9.  Is Prophylactic Intervention More Cost-effective Than the Treatment of Pathologic Fractures in Metastatic Bone Disease?

Authors:  Alan T Blank; Daniel M Lerman; Neeraj M Patel; Timothy B Rapp
Journal:  Clin Orthop Relat Res       Date:  2016-03-28       Impact factor: 4.176

Review 10.  Continuous Glucose Monitoring: Impact on Hypoglycemia.

Authors:  Cornelis A J van Beers; J Hans DeVries
Journal:  J Diabetes Sci Technol       Date:  2016-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.